Products & Services · Finite-lived intangible assets period increase (decrease)

Padcev — Finite-lived intangible assets period increase (decrease)

Pfizer Padcev — Finite-lived intangible assets period increase (decrease) remained flat by 0.0% to $150.00M in Q4 2025 compared to the prior quarter.

Analysis

StatementSegment
First reportedQ1 2023
Last reportedQ4 2025Feb 26, 2026
Rolls up toIntangible assets, increase (decrease)
Metric ID: pfe_segment_padcev_finite_lived_intangible_assets_period_increase_decrease

Historical Data

2 years
 FY'23FY'25
Value$2.10B$600.00M
YoY Change—-71.4%
Range$600.00M – $2.10B
Avg YoY Growth-71.4%
Median YoY Growth-71.4%

Frequently Asked Questions

What is Pfizer's padcev — finite-lived intangible assets period increase (decrease)?
Pfizer (PFE) reported padcev — finite-lived intangible assets period increase (decrease) of $150.00M in Q4 2025.